From Yahoo Finance: 2025-05-30 00:06:00

Avadel Pharmaceuticals plc (AVDL) will present 14 new abstracts, including four oral presentations, at SLEEP 2025, showcasing significant advances for LUMRYZ, its sodium oxybate treatment for narcolepsy. Interim results from the REFRESH study revealed that patients switching to LUMRYZ experienced improvements in excessive daytime sleepiness. Further data from the REST-ON trial showed normalization of ESS scores, reduction in hallucinations, and improvement in SRED symptoms. LUMRYZ, FDA-approved for adults and children aged 7 and older, eliminates middle-of-the-night dosing, supporting better sleep continuity. Avadel Pharmaceuticals plc continues to lead in innovative narcolepsy treatments.



Read more at Yahoo Finance: Avadel Pharmaceuticals plc (AVDL) Showcases LUMRYZ Success with 14 Abstracts, 4 Oral Presentations at SLEEP 2025